If you’re going to do only one thing, you’d better do it well. A company that could have learned that lesson earlier is Novo Nordisk, the drug maker that turned an obscure hormone into a weight-loss blockbuster. Its shares have more than halved since last summer, and last week it ousted its chief executive. His successor will inherit a company with vastly slimmed-down prospects.
如果你只打算做一件事，那就一定要把它做好。諾和諾德(Novo Nordisk)，這家將一種鮮為人知的激素變成減重爆款藥物的制藥公司，原本可以更早吸取這個教訓。自去年夏天以來，其股價已下跌超過一半，上周還罷免了首席執行官。他的繼任者將接手一家前景大幅縮水的公司。
您已閱讀13%（511字），剩余87%（3520字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。